Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.590 +0.060 (+3.92%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2025 Add to My Watchlist

Price and Volume

Volume	2,507,476
Open	1.540
Bid (Size)	1.570 (100)
Ask (Size)	1.590 (300)
Prev. Close	1.530
Today's Range	1.535 - 1.605
52wk Range	1.105 - 2.970
Shares Outstanding	52,346,231
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

December 08, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

December 08, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Performance

YTD	-39.5%	-39.5%
1 Month	+6.0%	+6.0%
3 Month	+11.2%	+11.2%
6 Month	-26.0%	-26.0%
1 Year	-45.2%	-45.2%

More News

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

December 01, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗

November 25, 2025

Via Stocktwits

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

November 25, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

November 12, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

A Look at Autolus Therapeutics's Upcoming Earnings Report ↗

November 11, 2025

Via Benzinga

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

November 03, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

October 30, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

October 27, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

October 20, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 15, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

September 16, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via Investor Brand Network

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via FinancialNewsMedia

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

August 12, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

July 24, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

July 21, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

Via Benzinga

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

Via FinancialNewsMedia

What 4 Analyst Ratings Have To Say About Autolus Therapeutics ↗

June 12, 2025

Via Benzinga

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?

Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.

What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?

Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?

The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market

What is the current price of Autolus Therapeutics plc - American Depositary Shares?

The current price of Autolus Therapeutics plc - American Depositary Shares is 1.590

When was Autolus Therapeutics plc - American Depositary Shares last traded?

The last trade of Autolus Therapeutics plc - American Depositary Shares was at 12/11/25 04:00 PM ET

What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?

The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 83.23M

How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?

Autolus Therapeutics plc - American Depositary Shares has 83M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.